Intel

Intel’s Insights from BioData World Congress 2016

One of our sponsors at BioData World Congress– Intel, prepared a post- event article with insights on the most burning topics that were discussed last week. Last week I was pleased to join a host of partners, customers and industry experts at the leafy Genome Campus in Cambridge, UK, for this year’s BioData World Congress. As one of the world’s leading …

Exciting developments in immunotherapy concerning CAR-T, CAR-T for solid tumours and immune checkpoint inhibitors

Immunotherapy has been around since the eighteenth century, when it was noticed that patients suffering with cancer would sometimes go into remission after suffering from a fever. However it wasn’t until the 1890s that someone started to carry out scientific research on this. William Coley carried out experiments where streptococcal cultures were injected into cancer patients, and regression was seen …

Rising costs may not be a result of orphan drugs

Published Online: Sep 12,2016 Laurie Toich, Assistant Editor From Daraprim’s price rising 5556% by Turing Pharmaceuticals under the leadership of Martin Shkreli, to the most recent pricing scandal with Mylan’s EpiPen, Americans have been faced with high out-of-pocket costs for many prescription drugs. Government institutions, such as the US Centers for Medicare and Medicaid, have begun crafting novel ways to reduce …

Rare diseases

Sharing the mission to conquer rare diseases

Closer collaboration between pharmaceutical companies and patient organizations will accelerate drug development At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases. Advocacy groups rely on their partners for financial and scientific support while providing access to repositories of patient data – the key to understanding rare diseases …

The World Immunotherapy Congress speaks to Renier Brentjens, Memorial Sloane Kettering

Earlier this year we got in touch with Renier Brentjens, Memorial Sloane Kettering, to talk about the industry ahead of his presentation at the World Immunotherapy congress taking place 14-16th November. 1) What do you think has been the biggest achievement within the immunotherapy sector in the last 12 months? I believe that the biggest achievement is a tie between …

Juno Therapeutics CAR-T JCAR015 trial – how you can meet them this November

In early July 2016, Juno Therapeutics stock value plummeted by an unprecedented 27% after three patients died in a clinical trial testing their lead cancer therapy. After this, US regulators put this trial on pause, causing questions to be asked about the safety of the new approaches to battling cancer. The trial in question was being tested on adults with …

The World Immunotherapy Congress speaks to Dr David Edwards, Preclinical Scientist, Cancer Research UK

Earlier this year we got in touch with Dr David Edwards, Preclinical Scientist, Cancer Research UK, to talk about the industry ahead of his talk at the World Immunotherapy congress taking place  this November. 1. What do you think has been the biggest achievement within the immunotherapy sector in the last 12 months? The emerging clinical data showing that anti-CTLA4/anti-PD1 therapy …